Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia
This article was originally published in The Pink Sheet Daily
Plus news on recent financing by Satori, Ceptaris, Vernalis and Exelixis
You may also be interested in...
In part two of this interview, the Alnylam chief executive discusses the thought process behind the biotech’s cutback in staff this past January and its $87 million cash raise in February.
The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.
Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.